PT1549750E - Moléculas modulares de transporte de antigénios (moléculas mat) para a modulação de reações imunitárias, correspondentes construções, processos e utilizações - Google Patents
Moléculas modulares de transporte de antigénios (moléculas mat) para a modulação de reações imunitárias, correspondentes construções, processos e utilizações Download PDFInfo
- Publication number
- PT1549750E PT1549750E PT38087185T PT03808718T PT1549750E PT 1549750 E PT1549750 E PT 1549750E PT 38087185 T PT38087185 T PT 38087185T PT 03808718 T PT03808718 T PT 03808718T PT 1549750 E PT1549750 E PT 1549750E
- Authority
- PT
- Portugal
- Prior art keywords
- mat
- module
- vector
- molecules
- antigen
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108010078791 Carrier Proteins Proteins 0.000 title 1
- 230000008105 immune reaction Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 230000005945 translocation Effects 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 230000001857 anti-mycotic effect Effects 0.000 abstract 1
- 239000002543 antimycotic Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 210000004748 cultured cell Anatomy 0.000 abstract 1
- 210000001808 exosome Anatomy 0.000 abstract 1
- 210000001723 extracellular space Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 210000003463 organelle Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 0 CCC(C1)C(*)CCC1C(C)* Chemical compound CCC(C1)C(*)CCC1C(C)* 0.000 description 3
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- QRMPKOFEUHIBNM-OCAPTIKFSA-N C[C@H]1CC[C@@H](C)CC1 Chemical compound C[C@H]1CC[C@@H](C)CC1 QRMPKOFEUHIBNM-OCAPTIKFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02022774A EP1408114B1 (de) | 2002-10-11 | 2002-10-11 | Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1549750E true PT1549750E (pt) | 2015-08-24 |
Family
ID=32010964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02022774T PT1408114E (pt) | 2002-10-11 | 2002-10-11 | Moléculas modulares de transportes de antigénios ( moléculas mat ) para modulação de respostas imunitárias, correspondentes construções, processos e utilizações. |
| PT38087185T PT1549750E (pt) | 2002-10-11 | 2003-10-09 | Moléculas modulares de transporte de antigénios (moléculas mat) para a modulação de reações imunitárias, correspondentes construções, processos e utilizações |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02022774T PT1408114E (pt) | 2002-10-11 | 2002-10-11 | Moléculas modulares de transportes de antigénios ( moléculas mat ) para modulação de respostas imunitárias, correspondentes construções, processos e utilizações. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7563866B2 (pt) |
| EP (2) | EP1408114B1 (pt) |
| JP (1) | JP4718183B2 (pt) |
| CN (1) | CN1738901B (pt) |
| AT (1) | ATE350480T1 (pt) |
| AU (1) | AU2003276089B2 (pt) |
| CA (1) | CA2502274C (pt) |
| CY (2) | CY1106387T1 (pt) |
| DE (1) | DE50209178D1 (pt) |
| DK (2) | DK1408114T3 (pt) |
| ES (2) | ES2279849T3 (pt) |
| HU (1) | HUE025092T2 (pt) |
| PT (2) | PT1408114E (pt) |
| SI (1) | SI1549750T1 (pt) |
| WO (1) | WO2004035793A1 (pt) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| HUE024953T2 (en) * | 2004-08-23 | 2016-02-29 | Yeda Res & Dev | Peptide inhibitors to mediate stress responses |
| US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| KR101441843B1 (ko) * | 2005-10-18 | 2014-09-17 | 내셔날 쥬이쉬 헬스 | 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법 |
| WO2007065633A1 (en) * | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| EP1792627A1 (en) * | 2005-12-05 | 2007-06-06 | ImVisioN AG | Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules |
| EP1976869A2 (en) * | 2005-12-23 | 2008-10-08 | Partnership&Corp. Technology Transfer | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation |
| US8449894B2 (en) * | 2006-05-26 | 2013-05-28 | City Of Hope | Aspergillus vaccine preparation and methods of making and using thereof |
| JP2010508828A (ja) * | 2006-11-10 | 2010-03-25 | マーシャル，バリー，ジェー． | 胃粘膜内へのペプチド送達方法及び装置 |
| CN101688228B (zh) * | 2007-03-13 | 2014-12-24 | 国家犾太健康中心 | 抗体产生的方法 |
| SG10201803982TA (en) | 2008-05-16 | 2018-07-30 | Taiga Biotechnologies Inc | Antibodies and processes for preparing the same |
| WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| US9169462B2 (en) * | 2008-07-21 | 2015-10-27 | Taiga Biotechnologies, Inc. | Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells |
| JP2010051764A (ja) * | 2008-07-29 | 2010-03-11 | Fujifilm Corp | 有害物質除去材及び有害物質除去方法 |
| EP2966084B1 (en) | 2008-08-28 | 2018-04-25 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
| CN101456905B (zh) * | 2008-12-05 | 2013-01-16 | 中国科学院海洋研究所 | 一种细菌五型分泌蛋白及其构建方法和应用 |
| WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| WO2010135277A2 (en) | 2009-05-18 | 2010-11-25 | Brown University | Cyclic-glur6 analogs, methods of treatment and use |
| WO2011025906A1 (en) | 2009-08-27 | 2011-03-03 | Brown University | Long term potentiation with cyclic-glur6 analogs |
| JP4921615B2 (ja) | 2010-01-25 | 2012-04-25 | パナソニック株式会社 | プロテインａを自己組織化膜上に固定する方法 |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| CN102918064B (zh) * | 2010-08-30 | 2015-03-11 | 松下健康医疗控股株式会社 | 在自组装单层上固定链霉亲和素的方法 |
| JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| JP5108166B2 (ja) | 2010-10-19 | 2012-12-26 | パナソニック株式会社 | グルコースオキシダーゼを自己組織化膜上に固定する方法 |
| JP6022470B2 (ja) * | 2010-11-24 | 2016-11-09 | タカラ バイオ ユーエスエー， インコーポレイテッド | 分散型タンパク質形質導入ドメインを含む誘導性発現系転写モジュレータおよびその使用方法 |
| US20140088017A1 (en) | 2011-05-23 | 2014-03-27 | Yeda Research And Development Co., Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| CN110643576A (zh) | 2012-07-20 | 2020-01-03 | 泰加生物工艺学公司 | 造血区室的增强的重建和自动重建 |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| EP3125933B1 (en) * | 2014-03-31 | 2022-05-18 | Boehringer Ingelheim Vetmedica GmbH | Improved modular antigen transportation molecules and uses therof |
| AU2016333474A1 (en) * | 2015-09-30 | 2018-03-22 | Boehringer Ingelheim Vetmedica Gmbh | Improved modular antigen transportation molecules and uses therof in animals |
| JP6799683B2 (ja) | 2016-12-02 | 2020-12-16 | タイガ バイオテクノロジーズ，インク． | ナノ粒子製剤 |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| EP3740497A4 (en) | 2018-01-17 | 2021-10-20 | NantBio, Inc. | INCREASED IMMUNOGENICITY FOR GPI ANCHORED ANTIGENS |
| KR102258231B1 (ko) * | 2019-10-22 | 2021-05-31 | 강릉원주대학교 산학협력단 | 미나리 유래 폴리펩티드 및 상기 폴리펩티드를 포함하는 약학적 조성물 |
| KR102365266B1 (ko) * | 2019-10-22 | 2022-02-23 | 강릉원주대학교산학협력단 | 미나리 유래 폴리펩티드 및 상기 폴리펩티드를 포함하는 약학적 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5633234A (en) * | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| US5565858A (en) * | 1994-09-14 | 1996-10-15 | Northrop Grumman Corporation | Electronic inventory system for stacked containers |
| US6060992A (en) * | 1998-08-28 | 2000-05-09 | Taiwan Semiconductor Manufacturing Co., Ltd. | Method and apparatus for tracking mobile work-in-process parts |
| AU5916799A (en) * | 1998-09-11 | 2000-04-03 | Key-Trak, Inc. | Object tracking system with non-contact object detection and identification |
| US6496806B1 (en) * | 1999-12-16 | 2002-12-17 | Samsys Technologies Inc. | Method and system for tracking clustered items |
| US6669089B2 (en) * | 2001-11-12 | 2003-12-30 | 3M Innovative Properties Co | Radio frequency identification systems for asset tracking |
| ATE384741T1 (de) * | 2003-04-24 | 2008-02-15 | Imvision Gmbh | Rekombinantes fel d 1 allergen |
-
2002
- 2002-10-11 DE DE50209178T patent/DE50209178D1/de not_active Expired - Lifetime
- 2002-10-11 PT PT02022774T patent/PT1408114E/pt unknown
- 2002-10-11 EP EP02022774A patent/EP1408114B1/de not_active Expired - Lifetime
- 2002-10-11 AT AT02022774T patent/ATE350480T1/de active
- 2002-10-11 ES ES02022774T patent/ES2279849T3/es not_active Expired - Lifetime
- 2002-10-11 DK DK02022774T patent/DK1408114T3/da active
-
2003
- 2003-10-09 WO PCT/EP2003/011190 patent/WO2004035793A1/de active Application Filing
- 2003-10-09 ES ES03808718.5T patent/ES2542329T3/es not_active Expired - Lifetime
- 2003-10-09 HU HUE03808718A patent/HUE025092T2/en unknown
- 2003-10-09 EP EP20030808718 patent/EP1549750B1/de not_active Expired - Lifetime
- 2003-10-09 JP JP2004544124A patent/JP4718183B2/ja not_active Expired - Lifetime
- 2003-10-09 AU AU2003276089A patent/AU2003276089B2/en not_active Expired
- 2003-10-09 CN CN2003801012557A patent/CN1738901B/zh not_active Expired - Lifetime
- 2003-10-09 DK DK03808718.5T patent/DK1549750T3/en active
- 2003-10-09 CA CA2502274A patent/CA2502274C/en not_active Expired - Lifetime
- 2003-10-09 PT PT38087185T patent/PT1549750E/pt unknown
- 2003-10-09 SI SI200332438T patent/SI1549750T1/sl unknown
-
2005
- 2005-04-11 US US11/102,883 patent/US7563866B2/en active Active
-
2007
- 2007-03-15 CY CY20071100367T patent/CY1106387T1/el unknown
-
2009
- 2009-06-22 US US12/488,751 patent/US20100098635A1/en not_active Abandoned
-
2015
- 2015-07-29 CY CY20151100662T patent/CY1116731T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004035793A1 (de) | 2004-04-29 |
| SI1549750T1 (sl) | 2015-09-30 |
| DE50209178D1 (de) | 2007-02-15 |
| EP1549750B1 (de) | 2015-04-29 |
| ES2542329T3 (es) | 2015-08-04 |
| EP1408114B1 (de) | 2007-01-03 |
| CN1738901A (zh) | 2006-02-22 |
| JP4718183B2 (ja) | 2011-07-06 |
| CA2502274A1 (en) | 2004-04-29 |
| AU2003276089B2 (en) | 2009-09-17 |
| JP2006502719A (ja) | 2006-01-26 |
| CY1106387T1 (el) | 2011-10-12 |
| PT1408114E (pt) | 2007-04-30 |
| US20050281816A1 (en) | 2005-12-22 |
| ES2279849T3 (es) | 2007-09-01 |
| ATE350480T1 (de) | 2007-01-15 |
| EP1408114A1 (de) | 2004-04-14 |
| US20100098635A1 (en) | 2010-04-22 |
| AU2003276089A1 (en) | 2004-05-04 |
| HUE025092T2 (en) | 2016-01-28 |
| DK1549750T3 (en) | 2015-07-13 |
| CN1738901B (zh) | 2010-05-12 |
| EP1549750A1 (de) | 2005-07-06 |
| CY1116731T1 (el) | 2017-03-15 |
| US7563866B2 (en) | 2009-07-21 |
| DK1408114T3 (da) | 2007-05-07 |
| CA2502274C (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1549750E (pt) | Moléculas modulares de transporte de antigénios (moléculas mat) para a modulação de reações imunitárias, correspondentes construções, processos e utilizações | |
| Walseng et al. | Ubiquitination regulates MHC class II-peptide complex retention and degradation in dendritic cells | |
| Idoyaga et al. | Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A | |
| Trumpfheller et al. | The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine | |
| US20060034865A1 (en) | Soluble MHC artificial antigen presenting cells | |
| Ng et al. | A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity | |
| Schutsky et al. | Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor | |
| CN102172397B (zh) | 树突细胞的体内靶向 | |
| GR3031026T3 (en) | Lysosomal targeting of immunogens. | |
| CN107236762A (zh) | 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法 | |
| Thomas et al. | Immune response gene control of determinant selection. III. Polypeptide fragments of insulin are differentially recognized by T but not by B cells in insulin immune guinea pigs. | |
| Colluru et al. | B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines | |
| Chamuleau et al. | MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation | |
| CN114853880B (zh) | Wt1抗原特异性t细胞受体及其抗肿瘤用途 | |
| CN109021114A (zh) | 联合两种单链抗体的双特异性嵌合抗原受体及表达载体 | |
| U'ren et al. | Vaccination with liposome–DNA complexes elicits enhanced antitumor immunity | |
| Harding | Intracellular organelles involved in antigen processing and the binding of peptides to class II MHC molecules | |
| Qin et al. | Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice | |
| Frankenburg et al. | Immunological activation following transcutaneous delivery of HR-gp100 protein | |
| ATE395422T1 (de) | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems | |
| US20220177544A1 (en) | Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells | |
| Finkelman et al. | Polyclonal activation of the murine immune system by an antibody to IgD. X. Evidence that the precursors of IgG1-secreting cells are newly generated membrane IgD+ B cells rather than the B cells that are initially activated by anti-IgD antibody. | |
| Ono et al. | Mouse melanoma antigen recognized by Lyt-2-and L3T4-cytotoxic T-lymphocytes | |
| Wynn et al. | Immuno-modulation of hormones controlling growth | |
| AU727624B2 (en) | Costimulation of T-cell proliferation by a chimeric bispecific costimulatory protein |